Illinois Municipal Retirement Fund lessened its holdings in Medtronic PLC (NYSE:MDT – Free Report) by 4.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 209,295 shares of the medical technology company’s stock after selling 8,952 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Medtronic were worth $18,060,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of MDT. BlackRock Inc. lifted its holdings in Medtronic by 0.7% during the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock worth $8,919,846,000 after buying an additional 838,220 shares during the last quarter. State Street Corp boosted its position in shares of Medtronic by 2.7% during the 2nd quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after acquiring an additional 1,658,301 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Medtronic by 5.4% during the 1st quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after acquiring an additional 1,343,220 shares in the last quarter. First Eagle Investment Management LLC boosted its position in shares of Medtronic by 37.2% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after acquiring an additional 3,739,288 shares in the last quarter. Finally, WCM Investment Management LLC purchased a new position in shares of Medtronic in the 1st quarter valued at about $965,922,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.
Recent Medtronic Headlines
Investors following MDT have been watching these headlines:
- Positive Sentiment: Reported short interest fell 83.5% in October to about 22.95 million shares, or roughly 1.8% of shares outstanding. That suggests fewer investors were positioned for a decline, though short-interest data alone does not indicate future performance. Article: Medtronic PLC Shares Shorted: Short Interest Down 83.5% in October
- Neutral Sentiment: A collaborative cardiac-therapy trial involving Medtronic has completed enrollment with 349 patients. Results are expected to be presented at Heart Rhythm Society 2027; a planned FDA submission depends on positive data, so the potential benefit remains uncertain. Article: Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
- Negative Sentiment: Medtronic initiated two Class II recalls affecting cardiac products. The OmniaSecure 3930M lead recall cites possible difficulties with fixation during implantation, while a CareLink SmartSync Programmer software issue may cause inaccurate estimates of implanted-device battery life. The recalls raise potential concerns about product reliability and could create costs or reputational risk, although the reports do not quantify their financial impact. Article: What Is Medtronic Facing After Two Class II Cardiac Device Recalls?
Analyst Upgrades and Downgrades
Check Out Our Latest Analysis on Medtronic
Insider Buying and Selling
In other Medtronic news, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the transaction, the executive vice president owned 42,186 shares of the company’s stock, valued at $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Michael Marinaro sold 10,420 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the sale, the executive vice president owned 105,916 shares of the company’s stock, valued at approximately $10,167,936. This represents a 8.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 61,903 shares of company stock worth $5,889,203 in the last quarter. 0.27% of the stock is owned by insiders.
Medtronic Stock Performance
NYSE MDT opened at $101.64 on Thursday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a market capitalization of $130.01 billion, a PE ratio of 25.03, a P/E/G ratio of 2.38 and a beta of 0.56. The company has a fifty day moving average of $93.34 and a two-hundred day moving average of $88.46.
Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The company had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same quarter last year, the company posted $1.26 earnings per share. The business’s quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, analysts expect that Medtronic PLC will post 5.98 earnings per share for the current year.
Medtronic Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.
Medtronic Company Profile
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
See Also
- Five stocks we like better than Medtronic
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
